Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
LIPOSYN II 20% is an intravenous lipid emulsion composed of safflower oil and soybean oil, designed to provide essential fatty acids and calories in parenteral nutrition. It is used in clinical nutrition support for patients unable to receive enteral feeding. The product functions as a caloric and nutritional substrate rather than a traditional pharmacological agent.
Late-stage lifecycle product with moderate competitive pressure (30) suggests declining team investment and potential for organizational restructuring.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent
Working on LIPOSYN II 20% offers limited career growth opportunity given its LOE-approaching status and minimal job pipeline. Positions available are primarily focused on maintaining market share and managing decline rather than driving innovation or expansion.
Worked on LIPOSYN II 20% at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.